Usefulness of Non TNF Usage in RA Patients

Shinshu University

Status and phase: Enrolling; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: Drug: "Salirumab"; Drug: Drug: "Abatacept"; Drug: Drug: "Tocilizmab"

Study type: Interventional

Funder types: Other

Identifiers

NCT03784261

NonTNF 2018

Details and patient eligibility

About

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:

1. Sarilumab treatment for 12 months
2. Tocilizmab treatment for 12 months
3. Abatacept treatment for 12 months

Enrollment: 90 estimated patients

Sex: All

Ages: 20 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

・RA patients

Exclusion criteria

• Not RA patients
• RA patients who are allergic to the drugs, refused to do this research, or who are pregnant

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

90 participants in 3 patient groups

SAR, usually subucutaneous injection every 2 weeks

Active Comparator group

Treatment:

Drug: Drug: "Abatacept"

Drug: Drug: "Salirumab"

Drug: Drug: "Tocilizmab"

TCZ, usually subucutaneous injection every 2 weeks

Active Comparator group

Treatment:

Drug: Drug: "Abatacept"

Drug: Drug: "Salirumab"

Drug: Drug: "Tocilizmab"

ABT, usually subucutaneous injection every week

Active Comparator group

Treatment:

Drug: Drug: "Abatacept"

Drug: Drug: "Salirumab"

Drug: Drug: "Tocilizmab"